HOME >> BIOLOGY >> NEWS
Medical research scientists make ethical value judgments in research

NEW YORK (May 14, 2007) -- Medical research scientists in public health and other areas routinely make ethical value judgments, even if they're not aware of it, according to a new Weill Cornell Medical College research study. And not only do these judgments not lead to bias necessarily, but they can make for better research.

Published in the current issue of European Journal of Epidemiology, the paper finds that the framing of the research question, identification of the problem, as well as the design and methodology of the study are all subject to value judgments by investigators.

To illustrate this point, the study focuses on how value judgments are made in epidemiological research of racial health disparities.

"Epidemiologists must endorse particular public policy aims of the research in order to make methodological decisions throughout the research process. In the case of research into racial disparities, the researcher decides how to define race -- whether by genetic markers or by census data. Both definitions are valid on their own, but in deciding which one to use, the scientist makes value assumptions about which would best promote the social aims of the research, such as eliminating racial disparities," says Dr. Inmaculada de Melo-Martn, the study's co-author and associate professor in the Division of Medical Ethics in the Department of Public Health at Weill Cornell Medical College.

"Also, scientists make value judgments in deciding which areas of research to pursue. For example, if the recommendations likely to result from additional genetic research are already part of standard medical practice, or if the new drugs resulting from genetic research would likely be too expensive for minority groups, then genetic research may not be the most effective way of trying to decrease racial health disparities," notes Dr. de Melo-Martn.

"In fact, many medical research scientists make these value judgments without
'"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
14-May-2007


Page: 1 2

Related biology news :

1. Ossurs PROPRIO FOOT takes the Gold 2007 Medical Design Excellence Award
2. Innovative smallpox vaccine research study to be conducted at Case Medical Center
3. Vitamin extends life in yeast, Dartmouth Medical School researchers find
4. Ossurs Proprio Foot walks away with 2007 Medical Design Excellence Award
5. University of Minnesotas 6th annual Design of Medical Devices Conference to be held April 17-19
6. Columbia University Medical Center awarded $3 million to drive Alzheimers genetics research
7. Burnham Institute for Medical Research announces affiliation with UC Santa Barbara
8. Yale scientist honored with Keio University Medical Science Prize
9. American College of Medical Genetics -- 2007 Annual Clinical Genetics Meeting Announcement
10. Breast Cancer Month story tips from Georgetown University Medical Center
11. Columbia University Medical Center receives major new NIH Clinical Science investment funds

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
(Date:3/3/2016)... MONTEREY, Calif. , March 3, 2016 /PRNewswire/ ... Partner, launched this week highlighting advancements in flexible, ... – a record setting attendance - have gathered ... in this fast-growing field of electronics. The Flex ... a focal point for companies, R&D organizations, and ...
(Date:3/2/2016)... March 2, 2016 ... addition of the  "Global Biometrics Market in ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics ... at a CAGR of around 27%   ... has announced the addition of the  "Global ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... N.J. , May 4, 2016  Bayer ... its oncology compound Stivarga ® (regorafenib) tablets ... carcinoma (HCC) has met its primary endpoint of ... study, called RESORCE, evaluated the efficacy and safety ... has progressed after treatment with sorafenib. The safety ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... growth, has leveraged recent innovations in biotechnology to help treat hormonal and stress ... hair loss, Nutrafol® has captured the hearts of key opinion leaders in the ...
(Date:5/3/2016)... ... 03, 2016 , ... Leading CEOs from biotech, pharmaceutical, and ... June 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/3/2016)... -- - And Other Rising Companies - ... Competitor Biologics  - Biosimilar Drug Producers - ... Who are the most important and promising ... sales potentials? Discover, in our updated survey, organisations, outlooks ... revenue forecasting. Visiongain,s new study ...
Breaking Biology Technology:
Cached News: